Arcutis Biotherapeutics (ARQT)
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company’s lead...
- Open
- 26.500
- High
- 26.560
- Low
- 24.540
- Prev. Close
- 26.460
- Volume
- 2.08M
- Turnover
- 52.38M
- Avg Price
- 25.126
- Bid/Ask Ratio
- -12.36%
- Amplitude
- 7.63%
- 52wk High
- 31.770
- Volume Ratio
- 2.08
- Turnover Ratio
- 2.25%
Arcutis Biotherapeutics Analyst Rating
View moreForecast & Rating
Aug 11, 2026Price forecast
$36.8850.02%
Forecast & RatingBuy
8analysts
- Strong buy62.50%
- Buy25.00%
- Hold12.50%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · 22 hours ago
Arcutis Biotherapeutics director Howard G. Welgus sells 4,730 common shares for $123,835.71
- PUBT · Aug 13 at 07:07 PM
Arcutis EVP, Chief Medical Officer Patrick Burnett disposes of USD 392,075.19 in common shares
- Tip Ranks · Aug 11 at 07:28 PM
Arcutis Biotherapeutics Earnings Call Highlights Growth Momentum
- PUBT · Aug 7 at 03:00 PM
Arcutis Biotherapeutics grants 143,500 RSUs, 37,000 stock options to new hires under inducement plan
- Simplywall · Aug 6 at 12:52 PM
Did Profitability, Higher 2026 Guidance, and New Commercial Leadership Just Recast Arcutis Biotherapeutics' (ARQT) Investment Narrative?
- Market Beat · Aug 5 at 10:07 PM
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Patrick Burnett Sells 955 Shares of Stock
